Major depressive disorder (RCT-backed, home-use device with a depression regulatory pathway).
Off-label · Not established (ungraded)
Cognitive-enhancement, 'brain-boost,' and longevity framing.
Low-amplitude direct current delivered across the scalp shifts cortical excitability without firing neurons, biasing—rather than driving—activity in the targeted region. The evidence base is now anchored by a fully remote, sham-controlled home-use randomized trial in major depression and by a regulatory pathway, with the Flow Neuroscience FL-100 reported as the first home-use non-invasive brain-stimulation device to receive an FDA premarket approval (PMA) for depression. A 2025 systematic review/meta-analysis of home-based tDCS in depressive disorders supports the depression signal, while consumer cognitive-enhancement and longevity claims remain unproven.
Origin & lineage
tDCS applies a weak constant scalp current to modulate cortical excitability; the modern clinical revival dates to Nitsche & Paulus (2000), who showed that anodal/cathodal direct current shifts human motor-cortex excitability in opposite directions.
Claimed mechanism
A weak constant current (about 1–2 mA) flows between scalp electrodes and shifts the resting membrane potential of underlying cortex (subthreshold), making targeted neurons more or less likely to fire rather than triggering action potentials directly. Effects are dose-dependent on current amplitude, electrode montage (anode/cathode placement), and stimulation duration.
Plausibility
Plausible / established (narrow) — a well-characterized subthreshold neuromodulation mechanism with controlled-trial and regulatory support confined chiefly to depression.
Evidence — grade B
Graded B because a positive fully remote sham-controlled home-use RCT and a depression-specific regulatory milestone establish efficacy for major depression, but outcomes across other indications are heterogeneous and strongly dependent on montage and dosing, which keeps the overall body of evidence short of A.
Cross-reference
Distinct from tACS (alternating current entraining oscillations) and from magnetic rTMS (suprathreshold magnetic pulses); as an electrical, subthreshold modality it sits within the Electroceuticals / Electrostimulation family.
Market
Makers: Flow Neuroscience; Soterix Medical; plus general-purpose research-grade tDCS systems used as class examples. Models: Flow FL-100 (home-use, prescription) as the depression-cleared example; clinical/research montaged tDCS units otherwise. Price: Flow FL-100 reported around USD 500–800 (prescription, planned 2026 launch); research devices vary.
Kernel — keep vs set aside
Keep — real substrate
Keep the dosed, subthreshold modulation of cortical excitability (current × montage × duration) as the working substrate, supported by a home-use depression RCT and a depression-specific regulatory milestone.
Set aside — claim
Set aside unproven consumer 'brain-boost,' general cognitive-enhancement, and longevity claims, which lack controlled-trial support and should not inherit the depression evidence.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
Reported FDA premarket approval (PMA, P230024) for the Flow Neuroscience FL-100 home-use device for moderate-to-severe major depressive disorder, decision dated 2025-12-08; clearance is a market-access fact, with efficacy resting on the trial evidence.
EU — MDR
tDCS depression devices (incl. Flow) have carried CE marking in the EU; specific MDR certificate status not confirmed in the resolved sources.
Anchored by a fully remote sham-controlled home-use RCT in major depression (Nature Medicine 2025) plus a 2025 systematic review/meta-analysis of home-based tDCS for depressive disorders (Scientific Reports); evidence level is controlled-trial plus meta-analytic, indication-specific to depression.